<HTML xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki  ltr ns-0 ns-subject page-Team_Fatih_Turkey_Anti_LPS"><DIV id="globalWrapper"><DIV id="top-section"><DIV id="p-logo"><A href="/Main_Page" title="Main Page">&quot;
	    </A></DIV><DIV id="menubar" class="left-menu noprint"><UL><LI class="selected"><A href="/Team:Fatih_Turkey/Anti_LPS">Page               </A></LI><LI class="new"><A href="/wiki/index.php?title=Talk:Team:Fatih_Turkey/Anti_LPS&amp;action=edit&amp;redlink=1">Discussion               </A></LI><LI><A href="/wiki/index.php?title=Team:Fatih_Turkey/Anti_LPS&amp;action=edit">View source               </A></LI><LI><A href="/wiki/index.php?title=Team:Fatih_Turkey/Anti_LPS&amp;action=history">History               </A></LI><LI style="color:#808080;cursor:default">teams</LI></UL></DIV><DIV class="right-menu noprint" id="menubar"><UL><LI id="pt-login"><A href="/wiki/index.php?title=Special:UserLogin&amp;returnto=Team:Fatih_Turkey/Anti_LPS" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o">Log in</A></LI></UL></DIV><DIV id="search-controls" class="noprint"><FORM action="/Special:Search" id="searchform"> </FORM></DIV></DIV><DIV id="content"><H1 class="firstHeading">Team:Fatih Turkey/Anti LPS</H1><DIV id="bodyContent"><H3 id="siteSub" class="noprint">From 2011.igem.org</H3><P><TITLE>Fatih_Turkey</TITLE><TABLE width="965" border="0" align="center"><TBODY><TR><TD width="959" height="208" align="center" valign="middle" background="https://static.igem.org/mediawiki/2011/0/02/Renkli.jpg"> </TD></TR><TR><TD width="188" align="center" valign="middle" bgcolor="#990000"><A href="https://2011.igem.org/Team:Fatih_Turkey"><SPAN class="style3">HOME</SPAN></A></TD><TD width="252" align="center" valign="middle" bgcolor="#695E0E"><A href="canvastown.html"><SPAN class="style3">CANVAS  TOWN</SPAN></A></TD><TD width="285" align="center" valign="middle" bgcolor="#1D3551"><A href="therainbowgraveyard.html"><SPAN class="style3">THE RAINBOW GRAVEYARD</SPAN></A></TD><TD width="176" align="center" valign="middle" bgcolor="#960C47"><A href="notebook.html"><SPAN class="style3"> NOTEBOOK</SPAN></A></TD></TR><TR><TD height="20" colspan="4" align="center" valign="middle" bgcolor="#1D3551"><A href="project.html"><SPAN class="style3">Anti-LPS</SPAN></A></TD></TR></TBODY></TABLE></P><P class="style10">Anti-LPS </P><P align="justify" class="style9">Lipopolysaccharide  (LPS),  or endotoxin,  is  the major mediator of septic shock, a serious complication of Gram-negative  bacterial  infections in humans. Molecules that bind LPS and neutralize its biological effects or enhance  its clearance could have important clinical applications. Limulus anti-LPS factor  (LALF) binds LPS tightly,  and,  in animal models, reduces mortality when administered before or after LPS challenge or bacterial infection. The  wedge-shaped molecule has a striking charge distribution and amphipathicity that suggest  how it  can insert  into membranes. The binding site for LPS probably involves an extended amphipathic loop, and it has  been proposed that two mammalian LPS-binding proteins will have a similar  loop.  The amphipathic  loop structure  may be used in the  design of molecules  with therapeutic properties against septic shock.</P><TABLE width="881" border="0"><TBODY><TR><TD width="875" height="198" align="center" valign="top"><P align="justify" class="style9">Horseshoe crabs  (Limulus polyphemus and Tachypleus tridentatus) are  ancient arachnids that possess a primitive circulatory  system, the hemolymph, containing only one kind of cell, the hemocyte. Exposure  of hemocytes to bacterial endotoxins [lipopolysaccharide (LPS)] results in the  activation of an intracellular coagulation cascade (Iwanaga et al., 1986), a  defense against microbial invasion. The system consists of several proteins,  including one that may inhibit the cascade, called anti-LPS factor(Morita et  al., 1985). Limulus anti-LPS factor (LALF) is a small (101 amino acids), basic  protein (Aketagawa et al., 1986; Muta et al., 1987), which binds and  neutralizes LPS (Wainwright et al., 1990) and has a strong anti-bacterial effect  on the growth of Gram-negative R-type bacteria (Morita et al., 1985)(22). Our  interest in determining the crystal structure of LALF arose from its potential  in designing molecules that would have therapeutic properties in humans. It has  been proposed that LALF has sequence similarity with ct-lactalbumin, a protein  that binds LPS in vitro (Aketagawa et al., 1986).</P></TD></TR></TBODY></TABLE><P> </P><TABLE width="840" border="0"><TBODY><TR><TD width="241"><P align="justify" class="style9">     LALF recognizes the lipid A portion of  individual soluble LPS molecules (Warren et al., 1992), which are obtained  below the critical micellar concentration. The simplest molecules that bind  lipid A with high affinity are the polymyxin family of antibiotics; these are  positively charged amphipathic cyclic oligopeptides linked to a single fatty  acid (Morrison and Jacobs, 1976).</P></TD></TR></TBODY></TABLE><P> </P><TABLE width="734" border="0"><TBODY><TR><TD height="32"><SPAN class="style11">Fig3,  Fig4 (A.  Hoess, S. Watson, G.R.Siber and R.Liddington.Crystal structure of an  endotoxin-neutralizing protein from the horseshoe crab, Limulus anti-LPS  factor, at 1.5 A resolution.)</SPAN></TD></TR></TBODY></TABLE><P> </P><TABLE width="926" border="0"><TBODY><TR><TD><P class="style11"> Freeze fracture electron micrographs of LPS. Alone (A), in  the presence of LALF supernatant (B) and precipitation (C).( Mechanism  of interaction of optimized Limulus-derived cyclic peptides with endotoxins:  thermodynamic, biophysical and microbiological analysis<SPAN class="style11">Jorg ANDR¨A, Jorg HOWE, Patrick GARIDEL, Manfred R OSSLE, Walter  RICHTER§, Jos´e LEIVA-LE ´ON_,  Ignacio </SPAN></P></TD></TR></TBODY></TABLE><P> </P><TABLE width="877" border="0"><TBODY><TR><TD width="871"><P align="justify">    Endotoxin-neutralizing protein protects  against Endotoxin-Induced Endothelial Barrier Dysfunction. Endotoxin-neutralizing  protein, a recombinant peptide that is derived from Limulus  antilipopolysaccharide  factor and targets lipid A, could block the effects of lipopolysaccharide on  protein tyrosine phosphorylation, actin organization, and movement of 14C-bovine serum  albumin across bovine pulmonary artery endothelial cell monolayers.  endotoxin-neutralizing protein crossprotected against lipopolysaccharide  derived from diverse gram-negative bacteria. LALF is a 11.8-kDa protein  isolated from the amebocyte, the single blood cell type found in the horseshoe crab  (13). The amebocyte-derived LALF as well as its recombinant form,  endotoxin-neutralizing protein (ENP), each binds to and neutralizes LPS (13, 18).  The LPS-binding site is 32 to 50 amino acids in length and forms an amphipathic  loop which binds to the lipid A portion of LPS (11, 15, 18). We therefore  studied whether a molecule such as ENP, which binds to lipid A and has been  shown to confer protection against the deleterious effect of LPS in vivo, could  block one or more of the sequential LPS-induced events leading to increased EC  monolayer permeability. In this work, we have studied whether ENP protects  against LPS-induced protein tyrosine phosphorylation, actin reorganization, and  loss of endothelial barrier function. the importance of the  amphipathic loop structure can be investigated by introducingappropriate  disulfide bonds to create a cyclic conformation. However, previous  investigations with cysteine- and non-cysteine- containing peptides derived from  TALF, a protein highly
          homologous  with LALF, showed little difference in LPS binding activity (23).</P></TD></TR></TBODY></TABLE>
       
      <P> </P><TABLE width="886" border="0"><TBODY><TR><TD align="center" valign="top"><P align="left" class="style11">Crystal structure of recombinant anti lipopolysaccharide  factor protein, which is homologous type of our Limulus anti po<SPAN class="style9">lysaccharide  factor (LALF) protein.NMR structure of rALF-Pm3, an anti-lipopolysaccaharide factor from shrimp: model of the possible lipid A- binding site.Yang Y, Boze H, </SPAN>Chemardin P, Padilla A, Moulin G, Tassanakajon A, Pugniere  M, Roquet F, Destoumieux-Garzon D, Gueguen Y, Bachere E, Aumelas A)</P></TD></TR></TBODY></TABLE><P align="justify">Considering that Limulus  anti-lipopolysaccharide factor (LALF) reduces the growth of gram negative  bacteria and terminates them; we determine that it can be used as a surface  protector. In our Project, we plan to design LALF protein producing system in a  specific bacteria that will not be harmed by this bactericide itself. To do  this, we needed a bacteria type that has no lip-A structure which is bound by  LALF. Thus, we decided to use Bacillus subtilis colonies which are the most  prefered gram positive bacteria in iGEM. In conclusion, our  “protector” bacteria affects on E. Coli mortally, therefore our remaining  region is cleared from E.coli. As a future aspect, a special covering material,  a biofilm for example, may be used as a cover sheet on surfaces that leads to  protection of bacterias.</P><TABLE width="200" border="0"><TBODY><TR><TD><P align="justify" class="style11">Binding  of 1 mg/ml biotinylated LALF-14 to lipid A and different  kinds of lipopolysaccharide adsorbed to a microtiter-plate (1.0 mg/ml).(<EM>From  MorphoSys GmbH, 80807 Munich, Germany, the Institute of Medical Microbiology  and Hygiene, Technical University of Munich, 81675 Munich, Germany, and the  Institute of Medical Immunology, Humboldt University of Berlin, 10098 Berlin,  Germany.</EM> High Affinity Endotoxin-binding and Neutralizing  Peptides Based on the Crystal Structure of Recombinant <EM>Limulus</EM>
          Anti-lipopolysaccharide Factor).The important  indication of this figure for our project is E.coli’s OD on 450 nm.</P></TD></TR></TBODY></TABLE><P> </P><TABLE width="899" border="0"><TBODY><TR><TD width="893" align="center" valign="top"><P class="style12">REFERENCES</P><P align="justify" class="style12">1. Alpert G, Baldwin G, Thompson C, Wainwright N,  Novitsky T J, Gillis  , Parsonnet J, Fleisher G R, Siber G R. Limulus  antilipopolysaccharide
              factor protects rabbits from meningococcal endotoxin  shock. J Infect Dis. 1992;165:494–500. [PubMed]
              2. Bannerman D D, Goldblum S E. Endotoxin induces  endothelial barrier dysfunction through protein tyrosine phosphorylation. Am J  Physiol.
              1997;273:L217–L226. [PubMed]
              3. Battafaraono R J, Dahlberg P S, Ratz C A, Johnston J  W, Gray B H, Haseman J R, Mayo K H, Dunn D L. Peptide derivatives of three  distinct
              lipopolysaccharide binding proteins inhibit  lipopolysaccharide-induced tumor necrosis factor-alpha secretion in vitro.  Surgery.
              1995;118:318–324. [PubMed]
              4. Cooperstock M S. Inactivation of endotoxin by  polymyxin B. Antimicrob Agents Chemother. 1974;6:422–425. [PMC free article]  [PubMed]
              5. Evans T J, Carpenter A, Moyes D, Martin R, Cohen J.  Protective effects of a recombinant amino-terminal fragment of human
              bactericidal/permeability-increasing protein in an animal  model of gram negative sepsis. J Infect Dis. 1995;171:153–160. [PubMed]
              6. Fletcher M A, Mckena T M, Quance J L, Wainwright N R,  Williams T J. Lipopolysaccharide detoxification by endotoxin neutralizing  protein. J
              Surg Res. 1993;55:147–154. [PubMed]
              7. Frey E A, Miller D S, Jahr T G, Sundan A, Bazil V,  Espevik T, Finlay B B, Wright S D. Soluble CD14 participates in the response of  cells to
              lipopolysaccharide. J Exp Med. 1992;176:1665–1671. [PMC  free article] [PubMed]
              8. Goldblum S E, Brann T W, Ding X, Pugin J, Tobias P S.  Lipopolysaccharide (LPS)-binding protein and soluble CD14 function as accessory  molecules for LPS-induced changes in endothelial barrier function, in vitro. J  Clin Invest. 1994;93:692–702. [PMC free article] [PubMed]
              9. Goldblum S E, Ding X, Brann T W, Campbell-Washington  J. Bacterial lipopolysaccharide induces actin reorganization, intercellular gap
              formation, and endothelial barrier dysfunction in  pulmonary vascular endothelial cells: concurrent F-actin depolymerization and  new actin
              synthesis. J Cell Physiol. 1993;157:13–23. [PubMed]
              10. Hirata M, Zhong J, Wright S C, Larrick J W. Structure  and functions of endotoxin-binding peptides derived from CAP18. Prog Clin Biol  Res.
              1995;392:317–326. [PubMed]
              11. Hoess A, Watson S, Siber G R, Liddington R. Crystal  structure of endotoxin-neutralizing protein from the horseshoe crab, Limulus  anti-LPS
              factor, at 1.5 A resolution. EMBO J. 1993;12:3351–3356.  [PMC free article] [PubMed]
              12. Levine D M, Parker T S, Donelly T M, Walsh A, Rubin A  L. In vivo protection against endotoxin by plasma high density lipoprotein.  Proc Natl
              Acad Sci USA. 1993;90:12040–12044. [PMC free article]  [PubMed]
              13. Morita T, Ohtsubo S, Nakamura T, Tanaka S, Iwanaga S,  Ohashi K, Niwa M. Isolation and biological activities of limulus anticoagulant
              (anti-LPS factor) which interacts with lipopolysaccharide  (LPS) J Biochem (Tokyo) 1985;97:1611–1620. [PubMed]
              14. Morrison D C, Jacobs D M. Binding of polymyxin B to  the lipid A portion of bacterial lipopolysaccharides. Immunochemistry.
              1976;13:813–818. [PubMed]
              15. Muta T, Miyata T, Tokunaga F, Nakamura T, Iwanaga S.  Primary structure of anti-lipopolysaccharide factor from American horseshoe  crab,
              Limulus polyphemus. J Biochem (Tokyo) 1987;101:1321–1330.  [PubMed]
              16. Netea M G, Demacker P N M, Kullberg B J, Boerman O C,  Verschueren I, Stalenhoef A F H, van der Meer J W M. Low-density lipoprotein
              receptor-deficient mice are protected against lethal  endotoxemia and severe Gram-negative infections. J Clin Invest.  1996;97:1366–1372.
              [PMC free article] [PubMed]
              17. Ulevitch R J, Tobias P S. Recognition of endotoxin by  cells leading to transmembrane signaling. Curr Opin Immunol. 1994;6:125–130.
              [PubMed]
              18. Wainwright N R, Miller R J, Paus E, Novitsky T J,  Fletcher M A, McKenna T M, Williams T. Endotoxin binding and neutralizing  activity by a
              protein from Limulus polyphemus. In: Levin J, Alving C R,  Munford R S, Stutz P L, editors. Cellular and molecular aspects of endotoxin
              reactions. New York, N.Y: Elsevier Science Publishers;  1990. pp. 315–325.
              19. Warren H S, Novitsky T J, Bucklin A, Kania S A, Siber  G R. Endotoxin neutralization with rabbit antisera to Escherichia coli J5 and  other
              gram-negative bacteria. Infect Immun. 1987;55:1668–1673.  [PMC free article] [PubMed]
              20. Weinstein S L, June C H, DeFranco A L.  Lipopolysaccharide-induced protein tyrosine phosphorylation in human  macrophages is mediated
              by CD14. J Immunol. 1993;151:3829–3838. [PubMed]
              21. A. Hoess, S. Watson, G.R.Siber and R.Liddington.Crystal  structure of an endotoxin-neutralizing protein from the horseshoe crab, Limulus  anti-LPS factor, at 1.5 A resolution.
              22. Lihua Wu, Chao-Ming Tsai and Carl E. Frasch.A  method purification of bacterial R-type LPS.
          23. Kloczewiak, M., Black, K. M., Loiselle, P.,  Cavaillon, J. M., Wainwright, N., and Warren, H. S. (1994) <EM>J. Infect. Dis. </EM>170, 1490–1497</P></TD></TR></TBODY></TABLE><P> </P><DIV class="printfooter">
Retrieved from &quot;<A href="http://2011.igem.org/Team:Fatih_Turkey/Anti_LPS">http://2011.igem.org/Team:Fatih_Turkey/Anti_LPS</A>&quot;</DIV></DIV></DIV><DIV id="footer-box" class="noprint"><DIV id="footer"><UL id="f-list"><LI id="t-recentchanges"><A href="/Special:RecentChanges" title="Recent changes">Recent changes</A></LI><LI id="t-whatlinkshere"><A href="/Special:WhatLinksHere/Team:Fatih_Turkey/Anti_LPS" title="List of all wiki pages that link here [j]" accesskey="j">What links here</A></LI><LI id="t-recentchangeslinked"><A href="/Special:RecentChangesLinked/Team:Fatih_Turkey/Anti_LPS" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</A></LI><LI id="t-specialpages"><A href="/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</A></LI><LI><A href="/Special:Preferences">My preferences</A></LI></UL></DIV><DIV id="footer"><UL id="f-list"><LI id="t-print"><A href="/wiki/index.php?title=Team:Fatih_Turkey/Anti_LPS&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</A></LI><LI id="t-permalink"><A href="/wiki/index.php?title=Team:Fatih_Turkey/Anti_LPS&amp;oldid=75124" title="Permanent link to this revision of the page">Permanent link</A></LI><LI id="privacy"><A href="/2011.igem.org:Privacy_policy" title="2011.igem.org:Privacy policy">Privacy policy</A></LI><LI id="disclaimer"><A href="/2011.igem.org:General_disclaimer" title="2011.igem.org:General disclaimer">Disclaimers</A></LI></UL></DIV></DIV></DIV></BODY></HTML>